Crossmark

ASO Visual Abstract: Expanding the Use of HIPEC in Ovarian Cancer at the Time of Interval Debulking Surgery to FIGO Stage IV After Six Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis of Perioperative and Oncologic Outcomes

Crossref DOI link: https://doi.org/10.1245/s10434-024-15200-4

Published Online: 2024-03-31

Published Print: 2024-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ghirardi, Valentina

Trozzi, Rita

Scanu, Francesca Romana

Giannarelli, Diana

Santullo, Francesco

Costantini, Barbara

Naldini, Angelica

Panico, Camilla

Frassanito, Luciano

Scambia, Giovanni

Fagotti, Anna
License Information

Text and Data Mining valid from 2024-03-31

Version of Record valid from 2024-03-31
More Information

Article History

First Online: 31 March 2024

Disclosure

: Anna Fagotti engages in relevant financial activities outside the submitted work that involves AstraZeneca/MSD, Johnson & Johnson, Fondazione Internazionale Menarini, and GlaxoSmithKline. The remaining authors have no conflicts of interests.

Document is current

Any future updates will be listed below